Supply of Interferon alfa-2b 18 million IU/3 mL injection vial by Merck Sharp & Dohme Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted to regulate the supply and advertising of therapeutic goods in Australia, was the basis for a notice issued by the delegate of the Secretary of the Department of Health and Ageing. The notice was published in the Gazette on January 29, 2013, and pertained to the temporary supply of interferon alfa-2b (HSA-free) (INTRON A) by Merck Sharp & Dohme Australia Pty Ltd, despite the products not conforming to the requirements of Therapeutic Goods Order 69. This non-compliance stemmed from the listing of the previous sponsor's details (Schering-Plough) on the carton labels instead of the current company's details. The policy objective behind this consent was to ensure a seamless transition and continued availability of essential therapeutic goods while maintaining regulatory standards. The consent was subject to specific conditions, including the maintenance of offices at the site of the previous sponsor's address and the continuation of telephone redirection services until the latest expiry date in the product range.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of entities and individuals involved in the supply, manufacture, and advertisement of therapeutic goods within Australia. This Act encompasses various therapeutic goods, including medicines, medical devices, blood, and tissues, and it governs their regulation to ensure public health and safety. The legislation applies to companies, manufacturers, importers, and suppliers of therapeutic goods, as well as to individuals such as healthcare professionals who may be involved in the distribution or administration of these goods. Geographically, the Act has a national reach, applying across the Commonwealth of Australia and potentially extending to state and territory regulations as they align with federal laws. The Act does not specify exclusions or thresholds explicitly in this context, but it allows for detailed regulation through subordinate instruments such as therapeutic goods orders and regulations which can provide further clarifications or impose additional conditions. This approach ensures that the Act can adapt to new scientific advancements, emerging health concerns, and changes in industry practices.

Key Provisions

The Therapeutic Goods Act 1989, under sections 14 and 14A, grants the delegate of the Secretary of the Department of Health and Ageing the authority to consent to the supply of specified therapeutic goods. In this instance, the delegate has provided consent for Merck Sharp & Dohme Australia Pty Ltd to supply two products: interferon alfa-2b (HSA-free) (INTRON A) 18 million IU/3 mL injection vial and interferon alfa-2b (HSA-free) (INTRON A) 10 million IU/1 mL injection vial, which are listed under Australian Register of Therapeutic Goods (ARTG) entries Aust R 60021 and Aust R 63274 respectively. The consent acknowledges that these products do not conform to the requirements of paragraph 3(2)(l) of Therapeutic Goods Order 69, as the carton labels list the previous sponsor's details (Schering-Plough) instead of the current supplier's (Merck Sharp & Dohme Australia Pty Ltd). The consent is contingent upon several conditions stipulated under subsection 15(1) of the Act. Firstly, the Company must maintain its offices at the site of the previous sponsor’s address, ensuring continuity and traceability. Secondly, telephone redirection from Schering-Plough’s contact numbers to the Company’s numbers must remain in place until the latest expiry date within the Schering-Plough product range is reached. This ensures that customers and stakeholders can continue to access relevant information and support without disruption. The obligations imposed on Merck Sharp & Dohme Australia Pty Ltd under this consent include maintaining the aforementioned office location and ensuring the continuity of communication channels. These obligations are critical to uphold the regulatory standards and maintain public trust in the therapeutic goods supplied. The consent will expire on specific dates for each product, namely April 30, 2013, for the 10 million IU/1 mL injection vial and October 31, 2013, for the 18 million IU/3 mL injection vial. In terms of compliance and enforcement, breaches of the conditions set forth in this consent could lead to various consequences. While the specific penalties are not detailed in the provided extract, under the Therapeutic Goods Act 1989, violations generally result in regulatory actions that may include fines, product recalls, or other administrative measures to ensure compliance with therapeutic goods regulations. The maximum penalties for breaches can be significant, reflecting the importance of adhering to the stipulated conditions and maintaining the integrity of the therapeutic goods supply chain.